Inclusion Criteria:

          -  Prior allogeneic HLA-matched stem cell transplantation

          -  Any of the following hematologic malignancies:

          -  Acute myeloid leukemia (AML)

          -  Acute lymphoblastic leukemia (ALL)

          -  Biphenotypic leukemia

          -  Chronic lymphoblastic leukemia (CLL)

          -  Hodgkin Lymphoma

          -  Non-Hodgkin Lymphoma (NHL)

          -  Multiple Myeloma (MM)

          -  Myelodysplastic syndrome (MDS)

          -  Presence of HLA2:01 and / or HLA44:02 and / or HLA-B*44:03, HLA-A*01:01; HLA-A*03:01;
             HLA-A*11:01;HLA A*24:02; HLA-A*29:02; HLA-A*32:01; HLA-B*07:02; HLA-B*08:01; HLA
             B*13:02; HLA-B*14:02; HLA-B*15:01; HLA-B*18:01; HLA-B*27:05; HLA B*35:01; HLA-B*40:01;
             or HLA-B*57:01

          -  At least 6 months after allogeneic hematopoietic stem cell transplantation

          -  Presence of detectable malignant disease post-transplantation in the form of
             molecular, cytogenetic or hematologic relapse of the malignant disorder.

          -  Eligible to receive cytoreductive chemotherapy

          -  Original stem cell donor available for leukocyte donation.

          -  ECOG performance status ≤2.

          -  Ability to provide written consent.

          -  Accessible for treatment and follow up.

          -  Presence of a targetable MiHA based on exome sequencing of the patient and donor

        Exclusion Criteria:

          -  Active acute GVHD > grade I

          -  Prior grade III-IV acute GVHD within the last year

          -  Uncontrolled chronic GVHD

          -  Prior administration of donor lymphocyte infusion (DLI)

          -  Use of T-cell depleting antibodies in the previous 30 days

          -  Treatment with immune suppressors (oral or parenteral steroids corresponding to a dose
             of prednisone greater than 7.5 mg/day, calcineurine inhibitors, rapamycin,
             mycophenolate mofetil, etc) during the last 30 days.

          -  Uncontrolled active infection

          -  Uncontrolled central nervous system involvement by leukemia cells (blasts).

          -  AST or ALT > 2.5 x ULN (CTCAE grade 2)

          -  Bilirubin > 1.5 x ULN (CTCAE grade 2)

          -  Creatinine clearance < 50 mL/min

          -  Positive test for human immunodeficiency virus (HIV)

          -  Positive pregnancy test (women of childbearing age only)

          -  Lactating women: the safety of this therapy on breast milk is not known.

          -  Estimated probability of surviving less than 3 months

          -  Known allergy to any of the components of GLIDE (e.g., dimethyl sulfoxide)

          -  Intercurrent illness or medical condition precluding safe administration of the
             planned protocol treatment or required follow-up.